troglitazone has been researched along with Liver Neoplasms in 27 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the PPARgamma agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1-10 microM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid." | 7.72 | Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines. ( Chen, JY; Cheng, AL; Hsu, C; Shen, YC, 2004) |
| " The aim of this study is to investigate the mechanisms of cell growth inhibition of hepatocellular carcinoma (HCC) cell lines by the PPARgamma ligand, troglitazone." | 7.71 | Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. ( Cioca, DP; Kawa, S; Kiyosawa, K; Tanaka, E; Yoshizawa, K, 2002) |
| "In our study, we examined whether human hepatocellular carcinoma (HCC) expresses peroxisome proliferator-activated receptor gamma (PPARgamma) and the effects of PPAR gamma activation by its selective ligands on cell growth and cell invasion in HCC cells." | 5.32 | Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. ( Kohgo, Y; Motomura, W; Nagamine, M; Okumura, T; Sawamukai, M; Takahashi, N; Tanno, S, 2004) |
| " In the present study, we examined whether PPARgamma is a possible target molecule for the prevention of cell growth and invasion by treatment with agonists (troglitazone, rosiglitazone) and antagonists (T0070907, GW9662) in four different hepatocellular carcinoma (HCC) cell lines." | 3.74 | A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. ( Baek, HA; Choi, HN; Chung, MJ; Jang, KY; Kim, KR; Lee, HJ; Moon, WS; Park, HS, 2007) |
| "Although the PPARgamma agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1-10 microM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid." | 3.72 | Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines. ( Chen, JY; Cheng, AL; Hsu, C; Shen, YC, 2004) |
| " The aim of this study is to investigate the mechanisms of cell growth inhibition of hepatocellular carcinoma (HCC) cell lines by the PPARgamma ligand, troglitazone." | 3.71 | Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. ( Cioca, DP; Kawa, S; Kiyosawa, K; Tanaka, E; Yoshizawa, K, 2002) |
| " In the present study, we investigated: 1) the expression of PPARgamma in both human hepatoma cell lines and 5 resected human hepatocellular carcinoma (HCC) tissues; 2) the growth-inhibitory effect of troglitazone, a PPARgamma ligand, on those hepatoma cells; and 3) the molecular mechanisms of troglitazone-induced cell-cycle arrest." | 3.71 | Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. ( Hanada, S; Harada, M; Hashimoto, O; Kawaguchi, T; Kimura, R; Koga, H; Kojiro, M; Sakisaka, S; Sasatomi, K; Sata, M; Takagi, T; Taniguchi, E; Ueno, T; Yano, H, 2001) |
| " In contrast, rosiglitazone (RSG), in the same group of agents, has no significant toxic effects and now is widely used." | 1.33 | Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. ( Katoh, M; Maniratanachote, R; Minami, K; Nakajima, M; Yokoi, T, 2005) |
| " Genes that are differentially expressed between the more toxic troglitazone/ciglitazone group and the less toxic rosiglitazone/pioglitazone group are involved in necrotic, apoptotic, and cell proliferative pathways." | 1.33 | Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. ( Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L, 2006) |
| "In surgically resected hepatocellular carcinoma (HCC) tissue, an increased expression in Skp2 was found in both the moderately differentiated HCCs and the poorly differentiated HCCs." | 1.32 | Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. ( Hanada, S; Harada, M; Koga, H; Kumashiro, R; Kumemura, H; Ohtsubo, M; Sata, M; Shishido, S; Taniguchi, E; Ueno, T; Yamashita, K, 2003) |
| "In our study, we examined whether human hepatocellular carcinoma (HCC) expresses peroxisome proliferator-activated receptor gamma (PPARgamma) and the effects of PPAR gamma activation by its selective ligands on cell growth and cell invasion in HCC cells." | 1.32 | Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. ( Kohgo, Y; Motomura, W; Nagamine, M; Okumura, T; Sawamukai, M; Takahashi, N; Tanno, S, 2004) |
| "The incidence of hepatocellular carcinoma was increased in female mice at 800 mg/kg." | 1.31 | Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. ( de la Iglesia, FA; Dethloff, LA; Gough, AW; Herman, JR; Masuda, H; McGuire, EJ; Parker, RF; Walsh, KM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 23 (85.19) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Zhang, L | 2 |
| Chen, Y | 1 |
| Fu, L | 1 |
| He, Y | 2 |
| Li, H | 1 |
| Lu, C | 1 |
| Zhu, P | 1 |
| Li, M | 1 |
| Duan, J | 1 |
| Fang, Z | 1 |
| König, B | 1 |
| Koch, A | 1 |
| Spielmann, J | 1 |
| Hilgenfeld, C | 1 |
| Hirche, F | 1 |
| Stangl, GI | 1 |
| Eder, K | 1 |
| Saha, S | 1 |
| Chan, DS | 1 |
| Lee, CY | 1 |
| Wong, W | 1 |
| New, LS | 1 |
| Chui, WK | 1 |
| Yap, CW | 1 |
| Chan, EC | 1 |
| Ho, HK | 1 |
| Yoshizawa, K | 1 |
| Cioca, DP | 1 |
| Kawa, S | 1 |
| Tanaka, E | 1 |
| Kiyosawa, K | 1 |
| Bae, MA | 1 |
| Rhee, H | 1 |
| Song, BJ | 1 |
| Hilding, A | 1 |
| Hall, K | 1 |
| Skogsberg, J | 1 |
| Ehrenborg, E | 1 |
| Lewitt, MS | 1 |
| Koga, H | 2 |
| Harada, M | 2 |
| Ohtsubo, M | 1 |
| Shishido, S | 1 |
| Kumemura, H | 1 |
| Hanada, S | 2 |
| Taniguchi, E | 2 |
| Yamashita, K | 1 |
| Kumashiro, R | 1 |
| Ueno, T | 2 |
| Sata, M | 2 |
| Motomura, W | 1 |
| Takahashi, N | 1 |
| Nagamine, M | 1 |
| Sawamukai, M | 1 |
| Tanno, S | 1 |
| Kohgo, Y | 1 |
| Okumura, T | 1 |
| Shen, YC | 1 |
| Hsu, C | 1 |
| Chen, JY | 1 |
| Cheng, AL | 1 |
| Maniratanachote, R | 1 |
| Minami, K | 1 |
| Katoh, M | 1 |
| Nakajima, M | 1 |
| Yokoi, T | 1 |
| Guo, YT | 1 |
| Leng, XS | 1 |
| Li, T | 1 |
| Zhao, JM | 1 |
| Lin, XH | 1 |
| Schaefer, KL | 1 |
| Wada, K | 1 |
| Takahashi, H | 1 |
| Matsuhashi, N | 1 |
| Ohnishi, S | 1 |
| Wolfe, MM | 1 |
| Turner, JR | 1 |
| Nakajima, A | 1 |
| Borkan, SC | 1 |
| Saubermann, LJ | 1 |
| Bouancheau, D | 1 |
| Buecher, B | 1 |
| Jarry, A | 1 |
| Simon, B | 1 |
| Masson, D | 1 |
| Cassagnau, E | 1 |
| Hamelin, R | 1 |
| Laboisse, CL | 1 |
| Bézieau, S | 1 |
| Denis, MG | 1 |
| Trubetskoy, O | 1 |
| Marks, B | 1 |
| Zielinski, T | 1 |
| Yueh, MF | 1 |
| Raucy, J | 1 |
| Chen, Q | 1 |
| Xia, Y | 1 |
| Qiu, Z | 1 |
| Yu, J | 1 |
| Qiao, L | 1 |
| Zimmermann, L | 1 |
| Ebert, MP | 1 |
| Zhang, H | 1 |
| Lin, W | 1 |
| Röcken, C | 1 |
| Malfertheiner, P | 1 |
| Farrell, GC | 1 |
| Guo, L | 1 |
| Sun, Y | 1 |
| Muskhelishvili, L | 1 |
| Blann, E | 1 |
| Dial, S | 1 |
| Shi, L | 1 |
| Schroth, G | 1 |
| Dragan, YP | 1 |
| Kim, KR | 1 |
| Choi, HN | 1 |
| Lee, HJ | 1 |
| Baek, HA | 1 |
| Park, HS | 1 |
| Jang, KY | 1 |
| Chung, MJ | 1 |
| Moon, WS | 1 |
| Chung, C | 1 |
| Doll, JA | 1 |
| Stellmach, VM | 1 |
| Gonzales, J | 1 |
| Surapureddi, S | 1 |
| Cornwell, M | 1 |
| Reddy, JK | 1 |
| Crawford, SE | 1 |
| Lee, WN | 1 |
| Lim, S | 1 |
| Bassilian, S | 1 |
| Bergner, EA | 1 |
| Edmond, J | 1 |
| Nordt, TK | 1 |
| Peter, K | 1 |
| Bode, C | 1 |
| Sobel, BE | 1 |
| Suzuki, Y | 1 |
| Urano, T | 1 |
| Ihara, H | 1 |
| Nakajima, T | 1 |
| Nagai, N | 1 |
| Takada, Y | 1 |
| Taminato, T | 1 |
| Takada, A | 1 |
| Sakisaka, S | 1 |
| Takagi, T | 1 |
| Kawaguchi, T | 1 |
| Sasatomi, K | 1 |
| Kimura, R | 1 |
| Hashimoto, O | 1 |
| Yano, H | 1 |
| Kojiro, M | 1 |
| Solomon, SS | 1 |
| Usdan, LS | 1 |
| Palazzolo, MR | 1 |
| Toyoda, M | 1 |
| Takagi, H | 1 |
| Horiguchi, N | 1 |
| Kakizaki, S | 1 |
| Sato, K | 1 |
| Takayama, H | 1 |
| Mori, M | 1 |
| Herman, JR | 1 |
| Dethloff, LA | 1 |
| McGuire, EJ | 1 |
| Parker, RF | 1 |
| Walsh, KM | 1 |
| Gough, AW | 1 |
| Masuda, H | 1 |
| de la Iglesia, FA | 1 |
1 review available for troglitazone and Liver Neoplasms
| Article | Year |
|---|---|
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
Topics: Carcinoma, Hepatocellular; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Interf | 2022 |
26 other studies available for troglitazone and Liver Neoplasms
| Article | Year |
|---|---|
Troglitazone inhibits hepatic oval cell proliferation by inducing cell cycle arrest through Hippo/YAP pathway regulation.
Topics: Cell Cycle Checkpoints; Cell Proliferation; Humans; Liver Neoplasms; PPAR gamma; Troglitazone | 2022 |
Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Fatty Acid Synthases; Glycerol-3-Pho | 2009 |
Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Biotransformation; Caspase 3; Cell Line, Tumor; Cell P | 2012 |
Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Chromans; Dose-Response Rel | 2002 |
Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Chro | 2003 |
Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism.
Topics: Carcinoma, Hepatocellular; Chromans; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Ag | 2003 |
Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; CDC2-CDC28 Kinases; Cell Cycle Proteins; Chromans; | 2003 |
Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Topics: Adenosine Triphosphatases; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Division; Chromans; | 2004 |
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Division; | 2004 |
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
Topics: Amino Acid Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chromans; Dose-Resp | 2005 |
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Chromans; Diethylnitrosamine; Gene Expression; | 2004 |
Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
Topics: Anilides; Anoikis; Benzamides; Carcinoma, Hepatocellular; Cell Adhesion; Cell Growth Processes; Cell | 2005 |
The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromans; Colonic Neoplasms; DNA Mutational A | 2005 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytoch | 2005 |
Effect of ecdysterone on glucose metabolism in vitro.
Topics: Animals; Cell Line, Tumor; Chromans; Dose-Response Relationship, Drug; Ecdysterone; Glucose; Humans; | 2006 |
Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Chromans; Cyclin-Dependent Kin | 2006 |
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Pro | 2006 |
A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Topics: Anilides; Benzamides; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Growth Proce | 2007 |
Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Cell Movement; Chromans; Clofibric Acid; Endothelium, Vascu | 2008 |
Fatty acid cycling in human hepatoma cells and the effects of troglitazone.
Topics: Carcinoma, Hepatocellular; Chromans; Fatty Acids; Gas Chromatography-Mass Spectrometry; Humans; Live | 1998 |
Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells.
Topics: Aorta; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Culture Media, Conditioned; Endothelium | 2000 |
Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in hepG2 cells.
Topics: Bezafibrate; Blotting, Northern; Carcinoma, Hepatocellular; Chromans; Culture Media, Conditioned; Do | 2001 |
Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
Topics: Carcinoma, Hepatocellular; Carrier Proteins; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Ce | 2001 |
Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s).
Topics: Animals; Autoradiography; Carcinoma, Hepatocellular; Chromans; Diabetes Mellitus, Type 2; Hypoglycem | 2001 |
A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Caspases; Cell Divis | 2002 |
Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone.
Topics: Adipose Tissue, Brown; Administration, Oral; Animals; Area Under Curve; Bone Marrow; Carcinogenicity | 2002 |